Letters to the Editor
Letter: is Helicobacter pylori behind Barrett's oesophagus and colorectal neoplasms?
Article first published online: 18 MAR 2013
© 2013 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 37, Issue 8, page 837, April 2013
How to Cite
Kountouras, J., Zavos, C., Chatzopoulos, D., Romiopoulos, I., Polyzos, S. A., Kapetanakis, N., Tsiaousi, E., Vardaka, E., Deretzi, G., Tsarouchas, G. and Katsinelos, P. (2013), Letter: is Helicobacter pylori behind Barrett's oesophagus and colorectal neoplasms?. Alimentary Pharmacology & Therapeutics, 37: 837. doi: 10.1111/apt.12247
- Issue published online: 18 MAR 2013
- Article first published online: 18 MAR 2013
- Manuscript Accepted: 24 JAN 2013
- Manuscript Received: 23 JAN 2013
Andrichi et al.'s meta-analysis showed that Barrett’s oesophagus (BO) was associated with an increased risk of both colorectal adenomas and colorectal cancer (CRC). They concluded that if the risk estimates for CRC in BO patients reflects a real relationship, an established association will warrant a search for common genetic or environmental risk factors.
Some genetic alterations are common in both conditions; we initially found that specialised intestinal metaplasia indicating BO appeared in a significant percentage of patients with colon tumours (12/23) compared with controls (2/14) and was associated with increased oesophageal mucosal expression of oncogenes Ki-67 and p53/Bcl-2 that indicated mainly increased proliferation leading to oncogenesis.
In this regard, Helicobacter pylori infection may be considered a promoter of both diseases. Our and others’ data indicate that H. pylori infection might contribute to oesophageal adenocarcinoma progress in subpopulations with gastro-oesophageal reflux disease and BO. In this respect, gastrin, induced by H. pylori infection, is an oncogenic growth factor contributing to oesophageal, gastric and colon carcinogenesis and, in particular, playing a potential causal effect on neoplastic progression in BO and left side CRC showing, for instance, anti-apoptotic activity through upregulation of the anti-apoptotic Bcl-2 and stimulation of mutagenic and tumourigenic cyclooxygenase-2 expression.[4-6]
Moreover, H. pylori infection is mostly frequent in colonic adenomas and tumour tissues (documented by immunohistochemical stain) and is accompanied by increased cell proliferation (mainly enhanced Ki-67 and Bcl-2 expression) and impaired apoptotic (decreased Bax) processes, thereby indicating its potential pathogenetic role.[6-8]
Apart from upper gastrointestinal tract (UGT), H. pylori infection might also cause chronic inflammatory colon mucosal damage and stimulate cancer stem cells and/or recruit bone-marrow–derived stem cells, which may ultimately facilitate UGT and colon tumour formation and progression.[8-10] However, further studies are needed to elucidate the proposed pathophysiological mechanisms involved in H. pylori-associated colon oncogenesis; its eradication might inhibit these oncogenic processes.
Declaration of personal and funding interests: None.
- 3Large intestine tumors (LI-TU) and ultra-short Barrett's esophagus (US-BE) [abstract]. Gut 2001; 49(Suppl. III): A1097., , , et al.
- 5Helicobacter pylori infection and colorectal carcinoma: pathologic aspects. J Gastrointest Oncol 2012; 3: 377–9., , , et al.
- 6Association of Helicobacter pylori infection with colorectal cancer. Immunogastroenterology 2013; 2: 47–56., , , et al.
- 7In situ H. pylori infection and oncogenes’ expression in patients with colorectal cancer [abstract]. Gut 2004; 53(Suppl. VI): A270., , , et al.
- 8Impact of Helicobacter pylori infection on colon oncogenesis. Am J Gastroenterol 2013; doi: 10.1038/ajg.2013.17 [Epub ahead of print]., , , et al.